CLRB Earnings Cellectar Biosciences, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–32 of 32
| Q2 2026 | 2026-06-30 | -0.57 | 2026-08-13 | 10-Q |
| Q1 2026 | 2026-03-31 | -1.33 | 2026-05-14 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | 0.75 | 2026-03-04 | 10-K |
| FY 2025 | 2025-12-31 | -8.35 | 2026-03-04 | 10-K |
| Q3 2025 | 2025-09-30 | -1.41 | 2025-11-13 | 10-Q |
| Q2 2025 | 2025-06-30 | -3.39 | 2025-08-14 | 10-Q |
| Q1 2025 | 2025-03-31 | -4.30 | 2025-05-13 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | 2.97 | 2025-03-13 | 10-K |
| FY 2024 | 2024-12-31 | -41.89 | 2025-03-13 | 10-K |
| Q3 2024 | 2024-09-30 | -12.13 | 2024-11-18 | 10-Q |
| Q2 2024 | 2024-06-30 | -5.43 | 2024-10-29 | 10-Q |
| Q1 2024 | 2024-03-31 | -27.30 | 2024-05-14 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -3.00 | 2024-03-27 | 10-K |
| FY 2023 | 2023-12-31 | -105.00 | 2024-03-27 | 10-K |
| Q3 2023 | 2023-09-30 | -46.50 | 2023-11-13 | 10-Q |
| Q2 2023 | 2023-06-30 | -27.00 | 2023-08-14 | 10-Q |
| Q1 2023 | 2023-03-31 | -28.50 | 2023-05-04 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | 9.75 | 2023-03-09 | 10-K |
| FY 2022 | 2022-12-31 | -121.50 | 2023-03-09 | 10-K |
| Q3 2022 | 2022-09-30 | -48.00 | 2022-11-03 | 10-Q |
| Q2 2022 | 2022-06-30 | -45.75 | 2022-08-05 | 10-Q |
| Q1 2022 | 2022-03-31 | -37.50 | 2022-05-10 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | -46.50 | 2022-03-21 | 10-K |
| FY 2021 | 2021-12-31 | -130.50 | 2022-03-21 | 10-K |
| Q3 2021 | 2021-09-30 | -36.38 | 2021-11-08 | 10-Q |
| Q2 2021 | 2021-06-30 | -42.75 | — | — |
| Q1 2021 | 2021-03-31 | -4.88 | — | — |
| FY 2020 | 2020-12-31 | -55.20 | — | — |
| Q3 2020 | 2020-09-30 | -4.50 | — | — |
| Q1 2017 | 2017-03-31 | -7.20 | 2017-05-11 | 10-Q |
| Q1 2016 | 2016-03-31 | 27.30 | 2016-05-12 | 10-Q |
| Q1 2015 | 2015-03-31 | -91.20 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.